## Note
nid: 1555451147551
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3), #AK_Step2_v11::!Shelf::#Cards_AnKing_Skipped, #AK_Step2_v11::!Shelf::IM::no_dupes, #AK_Step2_v11::!Shelf::IM::no_dupes::only_step2, #AK_Step2_v11::#OME_banner::Clinical::06_Infectious_Disease, #AK_Step2_v11::#Resources_by_rotation::IM::emma, #AK_Step2_v11::#Resources_by_rotation::IM::uw::infectious_disease::infectious_disease_dorian, #AK_Step2_v11::#Resources_by_rotation::IM::uw::infectious_disease::infectious_disease_zanki, #AK_Step2_v11::#Subjects::Neurology::15_Infection::Meningitis::Management, #AK_Step2_v11::#UWorld::1000-9999::3000-3999::3245, #AK_Step2_v11::Original_decks::Dorian::im::emma, #AK_Step2_v11::Original_decks::Dorian::im::uw::infectious_dz, #AK_Step2_v11::Original_decks::Zanki_Step_2::IM::ID
markdown: false

### Text
What are the recommended <i>empiric antibiotics</i> for
<u>immunocompromised</u> patients with suspected <b>bacterial
meningitis</b>?
<div>
  {{c1::Vancomycin
  <div>
    Ampicillin
  </div>
  <div>
    Cefepime}}
  </div>
</div>

### Extra
<div>
  <div>
    <div>
      <div>
        <div>
          <i><u>Cefepime</u> provides coverage for major organisms
          of bacterial meningitis (strep pneumo, neisseria
          meningitidis, group B strep, H Flu) and
          <b>pseudomonas</b>, <b>Listeria</b> (<u>ampicillin</u>),
          and cephalosporin-resistant <b>pneumococci</b>
          (<u>vancomycin</u>)</i>
        </div>
        <div style="font-weight: bold;"></div>
      </div>
    </div>
  </div>
</div>
<div>
  <i><img src="paste-1802554824458241.jpg"></i>
</div>
<div>
  <i><img src="crap!%20(1).png"></i>
</div>
<div>
  <i><img src="paste-2393671173406721.jpg"></i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/infectious-disease?ref=anki"><img src="_OME_AnkiFlashcards_Topic_4.png"></a>
</div>

### Additional Resources


### One by one

